Go Pro
→ Someone just dumped the biggest gold fund. (From Behind the Markets) (Ad)tc pixel Free ANIP Stock Alerts

ANI Pharmaceuticals (ANIP) Financials

ANI Pharmaceuticals logo
$78.02 +1.15 (+1.50%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$76.96 -1.05 (-1.35%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ANI Pharmaceuticals

Annual Income Statements for ANI Pharmaceuticals

This table shows ANI Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 15 3.93 -1.08 15 6.09 -23 -43 -50 17 -20 77
Consolidated Net Income / (Loss)		 15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Net Income / (Loss) Continuing Operations		 15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Total Pre-Tax Income 		22 8.68 16 20 3.16 -26 -56 -63 20 -22 96
Total Operating Income		 33 20 28 35 16 -16 -40 -35 47 0.58 111
Total Gross Profit		 64 80 98 129 143 121 116 178 305 364 542
Total Revenue		 76 129 177 202 207 208 216 316 487 614 883
Operating Revenue		 76 129 177 202 207 208 216 316 487 614 883
Total Cost of Revenue		 13 49 79 73 63 87 101 139 182 250 341
Operating Cost of Revenue		 13 49 79 73 63 87 101 139 182 250 341
Total Operating Expenses		 31 60 69 93 127 137 155 213 258 364 431
Selling, General & Admin Expense		 21 28 32 44 56 65 84 124 162 250 318
Research & Development Expense		 2.87 2.91 9.07 15 20 16 11 22 34 45 52
Depreciation Expense		 6.90 22 28 34 45 45 47 57 60 68 91
Impairment Charge		 0.00 6.69 0.90 0.00 0.08 0.45 2.37 - 0.00 7.60 0.77
Restructuring Charge		 - - - - - 0.00 0.00 5.68 1.13 0.00 0.00
Other Special Charges / (Income)		 - - - - 0.00 0.00 9.25 3.76 1.43 -5.97 -31
Total Other Income / (Expense), net		 -11 -11 -12 -15 -13 -9.95 -16 -27 -27 -23 -15
Interest Expense		 - - - - - - - 0.00 0.00 7.47 0.00
Interest & Investment Income		 -11 -11 -12 -15 -13 -9.45 -12 -28 -27 -18 -20
Other Income / (Expense), net		 0.04 -0.07 0.06 -0.55 -0.23 -0.49 -4.34 0.67 -0.16 2.27 4.76
Income Tax Expense		 6.36 4.74 17 4.56 -2.94 -3.41 -13 -15 1.09 -3.69 17
Preferred Stock Dividends Declared		 - - - - 0.00 0.00 0.19 1.63 1.63 1.63 1.16
Basic Earnings per Share		 $1.34 $0.34 ($0.09) $1.31 $0.51 ($1.88) ($3.40) ($3.05) $0.86 ($1.04) $3.50
Weighted Average Basic Shares Outstanding		 11.37M 11.45M 11.55M 11.68M 11.84M 11.96M 12.60M 16.26M 18.00M 19.32M 20.05M
Diluted Earnings per Share		 $1.32 $0.34 ($0.09) $1.30 $0.50 ($1.88) ($3.40) ($3.05) $0.85 ($1.04) $3.32
Weighted Average Diluted Shares Outstanding		 11.56M 11.57M 11.55M 11.77M 12.04M 11.96M 12.60M 16.26M 18.19M 19.32M 21.23M
Weighted Average Basic & Diluted Shares Outstanding		 11.50M 11.60M 12M 11.80M 12.11M 12.37M 17.27M 17.50M 21.08M 21.77M 22.42M

Quarterly Income Statements for ANI Pharmaceuticals

This table shows ANI Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 0.75 18 -2.69 -25 -11 15 8.14 26 27 29 25
Consolidated Net Income / (Loss)		 1.16 18 -2.29 -24 -10 16 8.55 27 27 29 25
Net Income / (Loss) Continuing Operations		 1.16 18 -2.29 -24 -10 16 8.55 27 27 29 25
Total Pre-Tax Income 		0.95 25 -2.29 -31 -14 20 11 34 31 40 37
Total Operating Income		 6.73 20 5.17 -21 -4.38 26 14 36 35 39 40
Total Gross Profit		 78 88 80 85 361 124 137 134 147 144 266
Total Revenue		 132 137 138 148 191 197 211 228 247 237 266
Operating Revenue		 132 137 138 148 191 197 211 228 247 237 266
Total Cost of Revenue		 53 49 58 63 -170 73 75 93 100 94 0.00
Total Operating Expenses		 72 68 75 106 365 98 123 98 112 105 226
Selling, General & Admin Expense		 44 48 53 79 70 77 82 77 83 74 92
Research & Development Expense		 9.87 11 7.30 10 17 11 17 12 12 11 15
Depreciation Expense		 15 15 15 16 23 23 23 23 23 21 20
Other Operating Expenses / (Income)		 - - - - - - - - - - 100
Other Special Charges / (Income)		 1.99 -5.26 0.36 0.83 -1.89 -12 1.28 -14 -5.64 -0.18 -0.62
Total Other Income / (Expense), net		 -5.78 5.02 -7.46 -11 -9.38 -6.21 -3.37 -2.44 -3.29 1.33 -3.36
Interest & Investment Income		 -5.75 -4.60 -4.66 -2.33 0.29 -5.48 -5.44 -4.73 -4.41 -3.77 -2.90
Other Income / (Expense), net		 -0.03 9.62 -2.80 -1.18 -9.68 -0.72 2.07 2.29 1.12 5.10 -0.47
Income Tax Expense		 -0.21 7.13 0.00 -7.33 -3.49 4.31 1.98 7.18 3.99 11 12
Preferred Stock Dividends Declared		 0.41 0.41 0.41 0.41 0.41 0.41 0.41 0.34 - 0.00 0.00
Basic Earnings per Share		 $0.04 $0.84 ($0.14) ($1.27) ($0.47) $0.70 $0.37 $1.19 $1.24 $1.31 $1.09
Weighted Average Basic Shares Outstanding		 18.00M 19.10M 19.32M 19.40M 19.32M 19.61M 19.83M 20.07M 20.05M 20.91M 21.16M
Diluted Earnings per Share		 $0.05 $0.82 ($0.14) ($1.27) ($0.45) $0.69 $0.36 $1.13 $1.14 $1.28 $1.05
Weighted Average Diluted Shares Outstanding		 18.19M 19.42M 19.32M 19.40M 19.32M 20.05M 20.31M 21.09M 21.23M 21.54M 21.92M
Weighted Average Basic & Diluted Shares Outstanding		 21.08M 20.97M 21.04M 21.03M 21.77M 21.66M 21.70M 22.47M 22.42M 22.75M 22.97M

Annual Cash Flow Statements for ANI Pharmaceuticals

This table details how cash moves in and out of ANI Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -14 -122 3.78 12 19 -54 92 -52 168 -76 141
Net Cash From Operating Activities		 17 27 39 67 46 15 3.32 -31 119 64 185
Net Cash From Continuing Operating Activities		 17 27 39 67 46 15 3.32 -31 119 64 185
Net Income / (Loss) Continuing Operations		 15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Consolidated Net Income / (Loss)		 15 3.93 -1.08 15 6.09 -23 -43 -48 19 -19 78
Depreciation Expense		 6.90 22 28 34 45 45 47 60 60 68 91
Amortization Expense		 6.83 7.28 7.67 8.47 7.02 1.88 2.51 3.96 3.92 14 1.36
Non-Cash Adjustments To Reconcile Net Income		 7.43 19 12 11 13 26 16 23 21 49 42
Changes in Operating Assets and Liabilities, net		 -19 -25 -7.55 -1.79 -25 -35 -20 -70 16 -48 -28
Net Cash From Investing Activities		 -33 -149 -108 -27 -28 -68 -105 -16 -19 -405 -34
Net Cash From Continuing Investing Activities		 -33 -149 -108 -27 -28 -68 -105 -16 -19 -405 -34
Purchase of Property, Plant & Equipment		 -2.18 -4.57 -10 -5.74 -6.64 -6.14 -2.56 -8.88 -8.87 -16 -14
Acquisitions		 -31 -144 -98 -22 -21 -62 -106 -7.61 -9.64 -402 -20
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 2.65 0.75 0.00 14 0.00
Net Cash From Financing Activities		 1.07 -0.73 72 -28 1.25 -1.44 195 -5.13 67 265 -9.94
Net Cash From Continuing Financing Activities		 1.07 -0.73 72 -28 1.25 -1.44 195 -5.13 67 265 -9.94
Repayment of Debt		 0.00 -0.29 -2.74 -31 -121 -16 75 -3.00 -3.00 -313 -10
Repurchase of Common Equity		 0.00 -2.50 - - -1.03 -1.52 -0.89 -1.96 -4.99 -11 -12
Payment of Dividends		 - - - - 0.00 0.00 -0.19 -1.63 -1.63 -1.63 -1.16
Issuance of Debt		 0.00 0.00 75 0.00 118 15 24 0.00 0.00 641 0.00
Issuance of Common Equity		 - - - - 0.00 0.00 70 0.00 81 0.00 0.00
Other Financing Activities, net		 1.07 2.07 0.09 2.69 5.74 0.62 2.07 1.46 -3.50 -50 14
Effect of Exchange Rate Changes		 - - - - - - - 0.00 0.00 -0.47 -0.23
Cash Interest Paid		 4.15 4.08 3.76 6.29 6.09 6.93 9.71 21 31 24 27
Cash Income Taxes Paid		 13 9.54 18 6.40 10 4.98 10 0.29 1.23 19 18

Quarterly Cash Flow Statements for ANI Pharmaceuticals

This table details how cash moves in and out of ANI Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 28 7.48 12 -95 -0.12 4.94 68 45 23 26 49
Net Cash From Operating Activities		 45 18 17 12 16 35 76 44 30 58 57
Net Cash From Continuing Operating Activities		 45 18 17 12 16 35 76 44 30 58 57
Net Income / (Loss) Continuing Operations		 1.16 18 -2.29 -24 -10 16 8.55 27 27 29 25
Consolidated Net Income / (Loss)		 1.16 18 -2.29 -24 -10 16 8.55 27 27 29 25
Depreciation Expense		 15 15 15 16 23 23 23 23 23 21 20
Amortization Expense		 0.95 0.10 0.10 3.35 11 0.32 0.34 0.34 0.35 0.36 0.36
Non-Cash Adjustments To Reconcile Net Income		 7.57 -21 14 17 28 5.27 31 -1.01 10 -6.48 14
Changes in Operating Assets and Liabilities, net		 20 6.24 -9.22 0.08 -35 -9.17 13 -4.52 -30 14 -2.47
Net Cash From Investing Activities		 -4.78 8.93 -4.45 -399 -11 -20 -6.91 -6.16 -1.40 -11 -3.05
Net Cash From Continuing Investing Activities		 -4.78 8.93 -4.45 -399 -11 -20 -6.91 -6.16 -1.40 -11 -3.05
Purchase of Property, Plant & Equipment		 -2.28 -4.58 -4.45 -4.81 -2.39 -2.47 -4.01 -6.10 -1.24 -6.07 -3.05
Net Cash From Financing Activities		 -12 -20 -1.45 291 -4.91 -9.91 -1.75 6.35 -4.64 -22 -4.65
Net Cash From Continuing Financing Activities		 -12 -20 -1.45 291 -4.91 -9.91 -1.75 6.35 -4.64 -22 -4.65
Repayment of Debt		 -0.75 -0.75 -0.75 -308 -4.01 -2.03 -2.03 -2.03 -4.06 -4.06 -4.06
Repurchase of Common Equity		 -0.23 -8.66 -1.30 -0.68 -0.32 -10 -0.55 -1.04 -0.61 -20 -0.81
Other Financing Activities, net		 -11 -9.91 1.01 -41 -0.18 2.53 1.24 9.76 0.04 2.20 0.23
Effect of Exchange Rate Changes		 - 0.00 - - -0.40 -0.30 0.84 0.58 -1.35 0.16 0.07
Cash Interest Paid		 8.01 7.95 8.21 3.08 5.15 8.90 4.97 8.46 4.61 7.82 4.42
Cash Income Taxes Paid		 0.30 0.85 16 0.01 1.85 0.29 16 0.14 1.06 -6.07 19

Annual Balance Sheets for ANI Pharmaceuticals

This table presents ANI Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 285 323 412 431 457 461 772 760 904 1,284 1,440
Total Current Assets		 193 103 132 153 188 170 322 344 520 528 753
Cash & Equivalents		 155 27 31 43 62 7.86 100 48 221 145 286
Restricted Cash		 - - - - - - 0.00 5.01 0.00 0.03 0.04
Short-Term Investments		 - - - - - - - - 0.00 6.31 9.13
Accounts Receivable		 22 46 59 65 72 96 129 165 162 222 281
Inventories, net		 13 26 38 41 48 61 82 105 111 137 143
Prepaid Expenses		 1.45 3.56 2.78 4.52 5.07 5.86 11 12 17 19 34
Plant, Property, & Equipment, net		 7.13 11 20 38 41 41 53 43 45 57 62
Total Noncurrent Assets		 86 209 260 240 229 250 397 373 340 699 625
Goodwill		 1.84 1.84 1.84 3.58 3.58 3.58 28 28 28 60 62
Intangible Assets		 66 176 230 202 180 189 294 252 209 542 480
Noncurrent Deferred & Refundable Income Taxes		 17 26 23 28 38 52 68 81 91 85 69
Other Noncurrent Operating Assets		 - 0.00 0.83 1.47 1.22 0.80 2.21 11 12 12 14
Total Liabilities & Shareholders' Equity		 285 323 412 431 457 461 772 760 904 1,284 1,440
Total Liabilities		 125 153 237 233 244 265 413 422 447 856 900
Total Current Liabilities		 12 32 39 166 62 79 88 99 145 194 278
Short-Term Debt		 - 0.00 3.35 3.26 9.94 13 0.85 0.85 13 9.20 17
Accounts Payable		 2.07 3.39 3.63 8.88 15 11 23 29 37 46 63
Accrued Expenses		 5.85 19 22 19 16 17 19 26 34 55 109
Current Deferred & Payable Income Tax Liabilities		 0.00 2.40 0.00 5.02 0.00 3.91 - 0.00 8.16 7.52 2.24
Current Employee Benefit Liabilities		 1.19 1.63 2.31 3.52 3.74 6.23 8.52 10 24 38 38
Other Current Liabilities		 2.65 5.76 8.27 125 17 27 36 33 30 39 50
Total Noncurrent Liabilities		 113 121 198 68 182 187 325 322 301 661 622
Long-Term Debt		 113 121 198 67 176 172 287 286 285 615 600
Other Noncurrent Operating Liabilities		 0.00 0.63 0.00 0.50 6.51 14 39 36 17 47 22
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 160 170 175 197 213 196 334 314 433 404 541
Total Preferred & Common Equity		 160 170 175 197 213 196 334 314 433 404 541
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 160 170 175 197 213 196 334 314 433 404 541
Common Stock		 164 173 179 187 201 214 388 404 514 520 596
Retained Earnings		 -4.35 -2.92 -4.01 11 18 -4.97 -48 -97 -80 -100 -23
Treasury Stock		 - 0.00 -0.26 -0.66 -0.72 -2.25 -3.14 -5.09 -10 -21 -33
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.38 -4.87 -11 -3.06 12 8.86 5.34 1.03
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for ANI Pharmaceuticals

This table presents ANI Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 765 859 890 915 921 1,287 1,292 1,343 1,408 1,422 1,494
Total Current Assets		 365 459 497 541 555 521 536 603 698 747 825
Cash & Equivalents		 68 162 193 229 240 145 150 218 263 311 360
Restricted Cash		 0.00 0.00 0.00 - - 0.04 0.03 0.04 0.04 0.04 0.04
Short-Term Investments		 - - - 9.66 6.94 8.30 5.39 5.72 8.86 15 16
Accounts Receivable		 175 173 179 172 166 196 220 226 253 255 274
Inventories, net		 104 104 107 114 125 148 137 138 146 143 143
Prepaid Expenses		 11 12 11 16 17 24 23 15 28 22 32
Plant, Property, & Equipment, net		 43 44 44 49 52 57 58 59 64 67 73
Total Noncurrent Assets		 357 356 349 325 314 709 698 681 646 608 595
Goodwill		 28 28 28 28 28 60 61 61 62 62 62
Intangible Assets		 239 230 220 196 183 570 538 520 500 467 450
Noncurrent Deferred & Refundable Income Taxes		 81 82 84 88 90 68 88 92 71 67 71
Other Noncurrent Operating Assets		 9.23 16 16 14 13 11 10 8.25 12 12 12
Total Liabilities & Shareholders' Equity		 765 859 890 915 921 1,287 1,292 1,343 1,408 1,422 1,494
Total Liabilities		 426 425 435 438 440 857 849 881 902 860 897
Total Current Liabilities		 126 123 134 137 140 190 202 237 271 240 284
Short-Term Debt		 24 26 25 1.26 1.69 8.44 11 14 15 19 21
Accounts Payable		 33 29 34 49 49 61 53 55 70 70 74
Accrued Expenses		 22 27 28 32 40 54 58 84 102 86 114
Current Deferred & Payable Income Tax Liabilities		 - - 0.59 11 0.00 0.00 14 3.29 0.00 5.30 3.53
Current Employee Benefit Liabilities		 13 11 15 9.53 16 30 22 33 33 16 27
Other Current Liabilities		 34 30 31 33 34 37 42 49 50 43 44
Total Noncurrent Liabilities		 300 302 301 301 300 667 647 645 632 620 613
Long-Term Debt		 285 285 285 285 284 618 612 608 605 594 589
Other Noncurrent Operating Liabilities		 14 17 16 16 16 48 36 36 27 26 24
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 315 410 430 452 456 406 419 437 506 562 597
Total Preferred & Common Equity		 315 410 430 452 456 406 419 437 506 562 597
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 315 410 430 452 456 406 419 437 506 562 597
Common Stock		 408 495 507 524 532 511 531 542 586 608 620
Retained Earnings		 -96 -90 -81 -62 -65 -90 -85 -77 -51 6.39 31
Treasury Stock		 -8.64 -9.18 -9.85 -19 -20 -21 -31 -32 -33 -53 -54
Accumulated Other Comprehensive Income / (Loss)		 11 14 14 9.41 8.33 5.37 3.61 3.31 2.81 0.48 -0.33
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for ANI Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ANI Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 36.36% 68.53% 37.49% 13.99% 2.47% 0.93% 3.67% 46.38% 53.87% 26.20% 43.78%
EBITDA Growth		 88.89% 6.79% 28.91% 20.38% -12.02% -55.72% -81.24% 415.30% 281.11% -28.95% 145.93%
EBIT Growth		 62.36% -38.90% 41.88% 22.64% -53.68% -202.40% -167.33% 21.58% 235.24% -107.37% 3,953.57%
NOPAT Growth		 -22.05% -60.65% -120.48% 1,565.46% 15.52% -135.52% -148.46% 11.33% 279.72% -99.08% 22,123.79%
Net Income Growth		 -46.52% -74.41% -127.35% 1,539.96% -60.67% -470.00% -88.94% -12.42% 139.21% -198.63% 522.94%
EPS Growth		 -49.03% -74.24% -126.47% 1,544.44% -61.54% -476.00% -80.85% 10.29% 127.87% -222.35% 419.23%
Operating Cash Flow Growth		 -21.64% 59.13% 43.49% 70.16% -31.97% -66.54% -78.24% -1,039.28% 481.24% -46.19% 189.34%
Free Cash Flow Firm Growth		 -3.66% -606.37% 35.34% 275.66% -154.07% 39.18% -312.24% 72.16% 246.82% -548.20% 135.22%
Invested Capital Growth		 53.74% 117.06% 31.87% -35.38% 50.68% 11.27% 46.75% 5.74% -6.54% 68.68% -4.25%
Revenue Q/Q Growth		 -3.78% 18.60% 5.41% 5.13% -4.24% 4.66% 1.73% 11.76% 8.33% 10.61% 6.83%
EBITDA Q/Q Growth		 -5.35% -2.26% 13.11% 7.52% -18.71% 22.61% -80.74% 2,362.17% 4.24% -4.38% 23.44%
EBIT Q/Q Growth		 -12.30% -20.04% 27.49% 11.50% -49.41% 23.08% -151.47% 44.89% 11.73% -119.94% 75.78%
NOPAT Q/Q Growth		 -47.49% -36.52% -111.66% 3,324.49% 7.85% 23.80% -152.83% 41.99% 4.07% -95.00% 57.33%
Net Income Q/Q Growth		 -54.11% -50.14% -114.40% 3,461.84% -62.75% 5.05% -92.76% 29.35% 40.34% -161.20% 93.09%
EPS Q/Q Growth		 -55.10% -50.00% -114.29% 6,400.00% -62.96% 4.57% -85.79% 34.13% 66.67% -92.59% 91.91%
Operating Cash Flow Q/Q Growth		 -25.92% 36.73% 10.43% 20.53% -32.95% -40.78% -66.10% 19.97% 70.38% -31.09% 8.50%
Free Cash Flow Firm Q/Q Growth		 -57.65% 1.50% -194.16% 496.53% -149.62% 69.15% -733.51% 75.94% 145.49% -12.98% 20.47%
Invested Capital Q/Q Growth		 -1.12% -3.21% 9.34% -37.04% 52.29% 2.33% 44.94% 1.73% -6.48% -0.30% 0.99%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 83.37% 62.07% 55.31% 63.77% 69.42% 58.19% 53.45% 56.13% 62.71% 100.00% 61.36%
EBITDA Margin		 60.89% 38.59% 36.18% 38.21% 32.81% 14.39% 2.60% 9.17% 22.70% 12.78% 23.62%
Operating Margin		 42.84% 15.61% 16.02% 17.54% 7.92% -7.68% -18.41% -11.15% 9.65% 0.10% 12.58%
EBIT Margin		 42.90% 15.55% 16.05% 17.27% 7.81% -7.92% -20.42% -10.94% 9.62% -0.56% 13.11%
Profit (Net Income) Margin		 20.14% 3.06% -0.61% 7.69% 2.95% -10.82% -19.71% -15.14% 3.86% -3.01% 8.87%
Tax Burden Percent		 70.75% 45.33% -6.58% 77.27% 193.03% 86.85% 76.00% 76.43% 94.50% 83.39% 81.78%
Interest Burden Percent		 66.38% 43.38% 57.60% 57.60% 19.58% 157.25% 127.01% 181.04% 42.45% 644.01% 82.68%
Effective Tax Rate		 29.26% 54.67% 106.58% 22.73% -93.03% 0.00% 0.00% 0.00% 5.50% 0.00% 18.22%
Return on Invested Capital (ROIC)		 23.59% 4.83% -0.62% 9.76% 11.46% -3.20% -6.13% -4.44% 8.02% 0.06% 10.30%
ROIC Less NNEP Spread (ROIC-NNEP)		 38.55% -17.15% 0.00% -2.83% -24.69% -10.99% -14.44% -15.61% -8.49% -6.83% 7.15%
Return on Net Nonoperating Assets (RNNOA)		 -13.34% -2.45% 0.00% -1.43% -8.48% -7.84% -9.24% -9.30% -3.31% -4.24% 5.87%
Return on Equity (ROE)		 10.25% 2.39% -0.62% 8.33% 2.97% -11.04% -15.37% -13.74% 4.72% -4.18% 16.16%
Cash Return on Invested Capital (CROIC)		 -18.77% -69.01% -28.11% 52.74% -28.98% -13.88% -44.02% -10.01% 14.79% -51.07% 14.64%
Operating Return on Assets (OROA)		 12.02% 6.58% 7.72% 8.26% 3.63% -3.60% -7.16% -4.52% 5.62% -0.32% 8.50%
Return on Assets (ROA)		 5.64% 1.29% -0.29% 3.68% 1.37% -4.91% -6.91% -6.25% 2.26% -1.69% 5.75%
Return on Common Equity (ROCE)		 10.25% 2.39% -0.62% 8.33% 2.97% -11.04% -14.68% -12.76% 4.42% -3.95% 15.75%
Return on Equity Simple (ROE_SIMPLE)		 9.60% 2.32% -0.62% 7.85% 2.86% -11.52% -12.76% -15.27% 4.34% -4.59% 0.00%
Net Operating Profit after Tax (NOPAT)		 23 9.10 -1.86 27 32 -11 -28 -25 44 0.41 91
NOPAT Margin		 30.31% 7.08% -1.05% 13.55% 15.28% -5.38% -12.89% -7.81% 9.12% 0.07% 10.28%
Net Nonoperating Expense Percent (NNEP)		 -14.96% 21.98% -0.62% 12.59% 36.15% 7.79% 8.31% 11.17% 16.52% 6.89% 3.15%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -4.11% 6.07% 0.04% 7.85%
Cost of Revenue to Revenue		 16.63% 37.93% 44.69% 36.23% 30.58% 41.81% 46.55% 43.87% 37.29% 0.00% 38.64%
SG&A Expenses to Revenue		 27.72% 21.64% 17.86% 21.86% 27.04% 31.17% 39.00% 39.21% 33.22% 40.63% 35.97%
R&D to Revenue		 3.77% 2.26% 5.13% 7.63% 9.59% 7.68% 5.26% 7.05% 7.04% 7.26% 5.85%
Operating Expenses to Revenue		 40.53% 46.46% 39.29% 46.23% 61.51% 65.88% 71.86% 67.25% 53.07% 99.90% 48.79%
Earnings before Interest and Taxes (EBIT)		 33 20 28 35 16 -17 -44 -35 47 -3.45 116
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 46 50 64 77 68 30 5.63 29 111 79 209
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.24 4.14 4.30 2.71 3.50 1.83 1.76 2.24 2.60 2.88 3.28
Price to Tangible Book Value (P/TBV)		 5.65 0.00 0.00 0.00 25.87 99.44 49.46 20.77 5.76 0.00 0.00
Price to Revenue (P/Rev)		 6.80 5.46 4.25 2.65 3.61 1.72 2.72 2.22 2.31 1.89 2.01
Price to Earnings (P/E)		 33.75 178.61 0.00 34.45 122.36 0.00 0.00 0.00 65.69 0.00 22.98
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 2.96% 0.56% 0.00% 2.90% 0.82% 0.00% 0.00% 0.00% 1.52% 0.00% 4.35%
Enterprise Value to Invested Capital (EV/IC)		 4.02 3.09 2.71 2.55 2.62 1.46 1.48 1.68 2.30 1.84 2.43
Enterprise Value to Revenue (EV/Rev)		 6.26 6.19 5.21 2.78 4.21 2.57 3.70 3.04 2.52 2.70 2.37
Enterprise Value to EBITDA (EV/EBITDA)		 10.28 16.04 14.40 7.29 12.83 17.89 142.06 33.13 11.12 21.14 10.05
Enterprise Value to EBIT (EV/EBIT)		 14.59 39.79 32.46 16.13 53.90 0.00 0.00 0.00 26.25 0.00 18.09
Enterprise Value to NOPAT (EV/NOPAT)		 20.65 87.44 0.00 20.55 27.53 0.00 0.00 0.00 27.68 4,061.24 23.07
Enterprise Value to Operating Cash Flow (EV/OCF)		 27.67 28.97 23.38 8.37 19.05 35.15 240.67 0.00 10.33 25.93 11.32
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 3.80 0.00 0.00 0.00 0.00 15.02 0.00 16.23
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.71 0.71 1.15 0.36 0.87 0.95 0.80 0.85 0.65 1.46 1.14
Long-Term Debt to Equity		 0.71 0.71 1.13 0.34 0.83 0.88 0.80 0.84 0.62 1.44 1.11
Financial Leverage		 -0.35 0.14 0.74 0.51 0.34 0.71 0.64 0.60 0.39 0.62 0.82
Leverage Ratio		 1.82 1.84 2.13 2.27 2.16 2.25 2.22 2.20 2.09 2.47 2.81
Compound Leverage Factor		 1.21 0.80 1.23 1.30 0.42 3.53 2.82 3.98 0.89 15.90 2.32
Debt to Total Capital		 41.47% 41.56% 53.55% 26.34% 46.61% 48.69% 44.48% 45.84% 39.43% 59.29% 53.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.89% 1.22% 2.49% 3.47% 0.13% 0.14% 1.74% 0.87% 1.51%
Long-Term Debt to Total Capital		 41.47% 41.56% 52.66% 25.13% 44.11% 45.21% 44.35% 45.70% 37.70% 58.42% 51.80%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.85% 3.98% 3.29% 2.36% 0.00%
Common Equity to Total Capital		 58.53% 58.44% 46.45% 73.66% 53.39% 51.31% 51.68% 50.19% 57.28% 38.35% 46.70%
Debt to EBITDA		 2.44 2.43 3.15 0.92 2.74 6.19 51.06 9.88 2.70 7.95 2.96
Net Debt to EBITDA		 -0.89 1.88 2.66 0.36 1.82 5.93 33.24 8.04 0.70 6.02 1.55
Long-Term Debt to EBITDA		 2.44 2.43 3.10 0.87 2.59 5.75 50.91 9.85 2.58 7.83 2.87
Debt to NOPAT		 4.90 13.25 -108.08 2.58 5.89 -16.56 -10.32 -11.60 6.71 1,526.71 6.79
Net Debt to NOPAT		 -1.78 10.25 -91.37 1.01 3.91 -15.86 -6.72 -9.45 1.73 1,156.85 3.55
Long-Term Debt to NOPAT		 4.90 13.25 -106.28 2.46 5.57 -15.38 -10.29 -11.57 6.42 1,504.21 6.60
Altman Z-Score		 3.87 3.61 2.81 2.11 2.79 1.37 1.22 1.47 2.60 1.49 2.43
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.48% 7.13% 6.24% 5.61% 2.56%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.38 3.22 3.35 0.92 3.04 2.17 3.68 3.46 3.57 2.72 2.71
Quick Ratio		 15.02 2.29 2.29 0.65 2.18 1.32 2.61 2.15 2.63 1.93 2.07
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -130 -84 148 -80 -49 -200 -56 82 -367 129
Operating Cash Flow to CapEx		 790.84% 601.66% 380.16% 1,167.93% 687.73% 248.85% 0.00% -383.99% 1,341.44% 2,351.84% 1,338.81%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -49.09 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.57 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.21 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.28 0.42 0.48 0.48 0.47 0.45 0.35 0.41 0.58 0.56 0.65
Accounts Receivable Turnover		 3.89 3.79 3.38 3.26 3.02 2.48 1.93 2.15 2.97 3.20 3.51
Inventory Turnover		 1.21 2.47 2.47 1.87 1.42 1.60 1.41 1.48 1.68 0.00 2.44
Fixed Asset Turnover		 12.36 14.19 11.26 6.89 5.25 5.10 4.60 6.60 11.08 12.11 14.80
Accounts Payable Turnover		 5.38 17.88 22.52 11.67 5.38 6.74 5.88 5.31 5.50 0.00 6.31
Days Sales Outstanding (DSO)		 93.80 96.24 108.03 111.93 121.02 147.00 189.41 169.57 122.78 114.01 103.88
Days Inventory Outstanding (DIO)		 300.60 148.04 147.58 195.51 256.22 228.17 258.48 245.97 217.73 0.00 149.64
Days Payable Outstanding (DPO)		 67.87 20.41 16.21 31.27 67.88 54.16 62.09 68.74 66.35 0.00 57.88
Cash Conversion Cycle (CCC)		 326.53 223.87 239.40 276.17 309.37 321.00 385.80 346.80 274.16 114.01 195.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 119 258 340 220 331 369 541 572 534 901 863
Invested Capital Turnover		 0.78 0.68 0.59 0.72 0.75 0.60 0.48 0.57 0.88 0.86 1.00
Increase / (Decrease) in Invested Capital		 42 139 82 -120 111 37 172 31 -37 367 -38
Enterprise Value (EV)		 478 796 921 561 869 537 800 961 1,229 1,660 2,096
Market Capitalization		 519 703 751 534 746 359 588 703 1,127 1,162 1,774
Book Value per Share		 $13.92 $14.64 $15.00 $16.64 $17.60 $15.84 $26.18 $17.96 $21.17 $19.20 $24.07
Tangible Book Value per Share		 $7.99 ($0.69) ($4.88) ($0.67) $2.38 $0.29 $0.93 $1.94 $9.57 ($9.42) ($0.06)
Total Capital		 274 290 376 268 399 381 646 625 756 1,053 1,158
Total Debt		 113 121 202 71 186 186 287 287 298 624 617
Total Long-Term Debt		 113 121 198 67 176 172 287 286 285 615 600
Net Debt		 -41 93 170 28 123 178 187 233 77 473 322
Capital Expenditures (CapEx)		 2.18 4.57 10 5.74 6.64 6.14 -0.09 8.13 8.87 2.72 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 26 44 65 -52 74 97 135 192 166 192 198
Debt-free Net Working Capital (DFNWC)		 181 71 96 -9.42 136 105 235 246 387 343 492
Net Working Capital (NWC)		 181 71 92 -13 126 92 234 245 374 334 475
Net Nonoperating Expense (NNE)		 7.76 5.17 -0.79 12 25 11 15 23 26 19 13
Net Nonoperating Obligations (NNO)		 -41 88 165 23 118 173 182 233 77 473 322
Total Depreciation and Amortization (D&A)		 14 30 36 42 52 47 50 64 64 82 93
Debt-free, Cash-free Net Working Capital to Revenue		 34.25% 33.97% 36.52% -26.01% 35.65% 46.59% 62.36% 60.82% 34.17% 31.25% 22.38%
Debt-free Net Working Capital to Revenue		 236.93% 55.25% 54.13% -4.67% 65.83% 50.37% 108.77% 77.65% 79.59% 55.86% 55.75%
Net Working Capital to Revenue		 236.93% 55.25% 52.24% -6.29% 61.01% 44.01% 108.38% 77.38% 76.90% 54.36% 53.77%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.34 $0.34 ($0.09) $1.31 $0.51 ($1.88) ($3.40) ($3.05) $0.86 ($1.04) $3.50
Adjusted Weighted Average Basic Shares Outstanding		 11.37M 11.45M 11.55M 11.68M 11.84M 11.96M 12.60M 16.26M 18.00M 19.32M 20.05M
Adjusted Diluted Earnings per Share		 $1.32 $0.34 ($0.09) $1.30 $0.50 ($1.88) ($3.40) ($3.05) $0.85 ($1.04) $3.32
Adjusted Weighted Average Diluted Shares Outstanding		 11.56M 11.57M 11.55M 11.77M 12.04M 11.96M 12.60M 16.26M 18.19M 19.32M 21.23M
Adjusted Basic & Diluted Earnings per Share		 $1.34 $0.00 $0.00 $0.00 $0.51 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.46M 11.60M 11.66M 11.86M 12.11M 12.37M 17.27M 17.50M 21.08M 21.77M 22.42M
Normalized Net Operating Profit after Tax (NOPAT)		 23 19 20 27 11 -11 -20 -18 47 1.55 66
Normalized NOPAT Margin		 30.31% 14.57% 11.57% 13.55% 5.57% -5.23% -9.12% -5.72% 9.61% 0.25% 7.52%
Pre Tax Income Margin		 28.48% 6.75% 9.25% 9.95% 1.53% -12.45% -25.94% -19.81% 4.08% -3.62% 10.84%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.46 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.83 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.31 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.45% -3.39% 8.65% -8.77% 1.48%
Augmented Payout Ratio		 0.00% 63.55% 0.00% 0.00% 16.92% -6.75% -2.54% -7.48% 35.21% -67.94% 17.06%

Quarterly Metrics And Ratios for ANI Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ANI Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 22,424,968.00 22,745,482.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 22,424,968.00 22,745,482.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 1.32 1.09
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 39.71% 28.70% 18.44% 12.52% 44.75% 43.43% 53.12% 53.58% 29.64% 20.46% 25.87%
EBITDA Growth		 24.48% 75.05% -38.76% -107.64% -15.74% 8.86% 130.65% 2,459.90% 130.34% 34.06% 51.54%
EBIT Growth		 276.43% 203.57% -80.82% -221.16% -309.98% -14.91% 573.83% 277.55% 563.28% 72.71% 150.53%
NOPAT Growth		 543.90% 121.95% -75.48% -192.68% -137.36% 40.79% 211.86% 298.69% 1,090.71% 38.75% 138.85%
Net Income Growth		 127.22% 1,165.25% -136.62% -343.12% -989.70% -13.87% 473.81% 210.14% 367.52% 88.07% 189.05%
EPS Growth		 117.24% 1,266.67% -148.28% -382.22% -1,000.00% -15.85% 357.14% 188.98% 353.33% 85.51% 191.67%
Operating Cash Flow Growth		 1,116.82% -14.73% -15.57% -61.22% -64.55% 91.53% 335.35% 253.17% 91.47% 66.83% -25.25%
Free Cash Flow Firm Growth		 253.37% 410.18% 598.54% -5,726.90% -911.35% -616.24% -585.08% 122.47% 118.55% 124.53% 116.78%
Invested Capital Growth		 -6.54% -9.70% -11.00% 58.22% 68.68% 73.77% 65.52% -5.47% -4.25% -6.73% -3.29%
Revenue Q/Q Growth		 -0.13% 4.39% 0.44% 7.46% 28.48% 3.44% 7.23% 7.78% 8.45% -3.88% 12.04%
EBITDA Q/Q Growth		 -33.05% 95.82% -61.63% -115.18% 838.45% 152.99% -18.69% 55.36% -4.30% 10.90% -8.09%
EBIT Q/Q Growth		 -62.63% 347.26% -92.09% -1,015.96% 35.23% 281.24% -37.33% 141.35% -6.84% 22.57% -9.09%
NOPAT Q/Q Growth		 -47.07% 77.94% -75.21% -496.96% 78.66% 770.59% -45.09% 152.91% 6.39% -6.08% -5.48%
Net Income Q/Q Growth		 -88.38% 1,476.36% -112.56% -956.67% 57.48% 252.60% -45.48% 211.35% 3.28% 7.28% -16.21%
EPS Q/Q Growth		 -88.89% 1,540.00% -117.07% -807.14% 64.57% 253.33% -47.83% 213.89% 0.89% 12.28% -17.97%
Operating Cash Flow Q/Q Growth		 39.08% -59.17% -4.68% -28.37% 27.14% 120.62% 116.66% -41.89% -31.07% 92.23% -2.92%
Free Cash Flow Firm Q/Q Growth		 639.61% 55.56% -4.37% -611.40% -6.65% 1.02% 10.14% 123.69% -11.98% 30.91% -38.54%
Invested Capital Q/Q Growth		 -6.48% -1.87% -0.91% 73.99% -0.30% 1.09% -5.62% -0.63% 0.99% -1.53% -2.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 59.42% 64.23% 58.20% 57.48% 189.17% 62.95% 64.70% 59.01% 59.42% 60.59% 100.00%
EBITDA Margin		 17.35% 32.54% 12.43% -1.76% 10.10% 24.70% 18.73% 27.00% 23.82% 27.49% 22.55%
Operating Margin		 5.11% 14.78% 3.74% -13.83% -2.30% 13.29% 6.57% 15.91% 14.07% 16.38% 15.21%
EBIT Margin		 5.08% 21.78% 1.72% -14.63% -7.37% 12.92% 7.55% 16.91% 14.53% 18.53% 15.03%
Profit (Net Income) Margin		 0.88% 13.25% -1.66% -16.29% -5.39% 7.96% 4.04% 11.68% 11.13% 12.42% 9.29%
Tax Burden Percent		 121.96% 71.87% 100.00% 76.72% 74.67% 78.46% 81.23% 78.75% 87.33% 73.32% 66.61%
Interest Burden Percent		 14.15% 84.63% -96.54% 145.16% 97.92% 78.47% 65.93% 87.73% 87.71% 91.43% 92.76%
Effective Tax Rate		 -21.96% 28.14% 0.00% 0.00% 0.00% 21.54% 18.77% 21.25% 12.67% 26.68% 33.39%
Return on Invested Capital (ROIC)		 5.48% 9.95% 2.56% -7.29% -1.38% 9.79% 5.78% 11.78% 12.30% 12.60% 11.72%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.94% 12.44% -3.71% -10.61% -4.00% 7.90% 4.53% 11.31% 11.58% 12.85% 11.01%
Return on Net Nonoperating Assets (RNNOA)		 0.37% 4.40% -0.76% -7.07% -2.48% 4.42% 2.11% 9.93% 9.50% 9.66% 6.58%
Return on Equity (ROE)		 5.85% 14.35% 1.80% -14.36% -3.86% 14.21% 7.89% 21.71% 21.81% 22.25% 18.30%
Cash Return on Invested Capital (CROIC)		 14.79% 18.78% 18.56% -43.98% -51.07% -53.26% -47.81% 12.19% 14.64% 18.13% 16.84%
Operating Return on Assets (OROA)		 2.97% 13.42% 1.04% -7.46% -4.14% 7.89% 4.99% 10.38% 9.42% 12.61% 10.37%
Return on Assets (ROA)		 0.51% 8.16% -1.00% -8.31% -3.03% 4.86% 2.67% 7.17% 7.21% 8.45% 6.41%
Return on Common Equity (ROCE)		 5.48% 13.48% 1.70% -13.56% -3.64% 13.45% 7.47% 21.13% 21.25% 21.70% 17.87%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 7.87% 5.93% -1.75% 0.00% -5.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 8.20 15 3.62 -14 -3.06 21 11 29 30 29 27
NOPAT Margin		 6.23% 10.62% 2.62% -9.68% -1.61% 10.43% 5.34% 12.53% 12.29% 12.01% 10.13%
Net Nonoperating Expense Percent (NNEP)		 4.55% -2.50% 6.27% 3.32% 2.62% 1.89% 1.25% 0.47% 0.72% -0.26% 0.71%
Return On Investment Capital (ROIC_SIMPLE)		 1.12% - - - -0.30% 1.97% 1.07% 2.53% 2.62% 2.42% 2.23%
Cost of Revenue to Revenue		 40.58% 35.77% 41.80% 42.52% -89.17% 37.05% 35.30% 40.99% 40.58% 39.41% 0.00%
SG&A Expenses to Revenue		 33.77% 34.94% 38.27% 53.31% 36.58% 38.82% 38.69% 33.65% 33.51% 31.02% 34.45%
R&D to Revenue		 7.49% 7.65% 5.29% 6.83% 8.73% 5.36% 7.82% 5.40% 4.96% 4.46% 5.54%
Operating Expenses to Revenue		 54.32% 49.45% 54.46% 71.31% 191.46% 49.66% 58.13% 43.10% 45.34% 44.21% 84.79%
Earnings before Interest and Taxes (EBIT)		 6.69 30 2.37 -22 -14 25 16 39 36 44 40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 23 45 17 -2.61 19 49 40 61 59 65 60
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.60 3.22 2.93 3.09 2.88 3.48 3.24 3.93 3.28 3.07 3.15
Price to Tangible Book Value (P/TBV)		 5.76 6.40 5.46 0.00 0.00 0.00 0.00 0.00 0.00 52.80 22.18
Price to Revenue (P/Rev)		 2.31 2.82 2.48 2.26 1.89 2.16 1.89 2.40 2.01 1.87 1.92
Price to Earnings (P/E)		 65.69 42.96 52.60 0.00 0.00 0.00 0.00 50.96 22.98 18.87 17.44
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.52% 2.33% 1.90% 0.00% 0.00% 0.00% 0.00% 1.96% 4.35% 5.30% 5.73%
Enterprise Value to Invested Capital (EV/IC)		 2.30 2.92 2.69 1.94 1.84 2.14 2.14 2.73 2.43 2.37 2.55
Enterprise Value to Revenue (EV/Rev)		 2.52 2.96 2.60 3.16 2.70 2.89 2.46 2.83 2.37 2.18 2.16
Enterprise Value to EBITDA (EV/EBITDA)		 11.12 11.79 11.78 21.35 21.14 23.65 17.51 13.82 10.05 8.93 8.62
Enterprise Value to EBIT (EV/EBIT)		 26.25 22.87 24.59 101.37 0.00 0.00 323.32 35.45 18.09 14.97 13.37
Enterprise Value to NOPAT (EV/NOPAT)		 27.68 32.27 36.67 214.32 4,061.24 430.92 172.76 40.46 23.07 20.47 18.54
Enterprise Value to Operating Cash Flow (EV/OCF)		 10.33 13.21 12.43 18.88 25.93 24.16 13.20 13.69 11.32 9.65 11.18
Enterprise Value to Free Cash Flow (EV/FCFF)		 15.02 14.74 13.67 0.00 0.00 0.00 0.00 21.80 16.23 12.60 14.86
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.65 0.60 0.60 1.45 1.46 1.40 1.35 1.23 1.14 1.09 1.02
Long-Term Debt to Equity		 0.62 0.60 0.59 1.44 1.44 1.38 1.32 1.20 1.11 1.06 0.99
Financial Leverage		 0.39 0.35 0.21 0.67 0.62 0.56 0.46 0.88 0.82 0.75 0.60
Leverage Ratio		 2.09 2.06 1.95 2.46 2.47 2.40 2.40 2.88 2.81 2.70 2.68
Compound Leverage Factor		 0.30 1.74 -1.88 3.57 2.42 1.88 1.58 2.52 2.47 2.47 2.49
Debt to Total Capital		 39.43% 37.48% 37.31% 59.26% 59.29% 58.42% 57.40% 55.09% 53.30% 52.19% 50.55%
Short-Term Debt to Total Capital		 1.74% 0.17% 0.22% 0.80% 0.87% 1.07% 1.26% 1.36% 1.51% 1.64% 1.77%
Long-Term Debt to Total Capital		 37.70% 37.32% 37.09% 58.46% 58.42% 57.35% 56.14% 53.73% 51.80% 50.55% 48.78%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 3.29% 3.26% 3.24% 2.35% 2.36% 2.33% 2.29% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 57.28% 59.26% 59.44% 38.39% 38.35% 39.25% 40.30% 44.91% 46.70% 47.81% 49.45%
Debt to EBITDA		 2.70 2.20 2.41 7.63 7.95 7.55 5.93 3.67 2.96 2.73 2.49
Net Debt to EBITDA		 0.70 0.37 0.33 5.76 6.02 5.67 3.80 2.06 1.55 1.28 0.96
Long-Term Debt to EBITDA		 2.58 2.19 2.39 7.53 7.83 7.41 5.80 3.58 2.87 2.64 2.40
Debt to NOPAT		 6.71 6.03 7.50 76.59 1,526.71 137.65 58.51 10.74 6.79 6.24 5.35
Net Debt to NOPAT		 1.73 1.00 1.02 57.85 1,156.85 103.36 37.48 6.04 3.55 2.93 2.05
Long-Term Debt to NOPAT		 6.42 6.01 7.45 75.56 1,504.21 135.13 57.22 10.48 6.60 6.05 5.16
Altman Z-Score		 2.45 3.11 2.86 1.47 1.46 1.84 1.80 2.31 2.25 2.39 2.47
Noncontrolling Interest Sharing Ratio		 6.24% 6.09% 5.43% 5.61% 5.61% 5.40% 5.27% 2.65% 2.56% 2.47% 2.35%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.57 3.95 3.97 2.74 2.72 2.66 2.54 2.58 2.71 3.12 2.91
Quick Ratio		 2.63 3.00 2.95 1.84 1.93 1.86 1.90 1.94 2.07 2.43 2.29
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 46 71 68 -347 -370 -366 -329 78 69 90 55
Operating Cash Flow to CapEx		 1,963.14% 0.00% 391.41% 259.23% 662.49% 1,414.35% 1,888.69% 721.86% 2,441.08% 961.06% 1,855.57%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -46.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 1.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 1.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.58 0.62 0.61 0.51 0.56 0.61 0.66 0.61 0.65 0.68 0.69
Accounts Receivable Turnover		 2.97 2.98 3.18 2.96 3.20 3.43 3.82 3.68 3.51 3.88 3.91
Inventory Turnover		 1.68 1.77 1.81 1.75 0.00 0.19 0.31 0.48 2.44 2.58 2.04
Fixed Asset Turnover		 11.08 11.27 11.23 11.01 12.11 12.63 13.48 13.75 14.80 14.74 14.77
Accounts Payable Turnover		 5.50 4.70 5.40 4.70 0.00 0.47 0.79 1.09 6.31 5.90 4.47
Days Sales Outstanding (DSO)		 122.78 122.43 114.80 123.28 114.01 106.34 95.66 99.09 103.88 94.00 93.29
Days Inventory Outstanding (DIO)		 217.73 205.70 201.24 208.06 0.00 1,920.11 1,179.91 755.85 149.64 141.66 178.83
Days Payable Outstanding (DPO)		 66.35 77.66 67.60 77.60 0.00 783.25 461.88 335.39 57.88 61.91 81.58
Cash Conversion Cycle (CCC)		 274.16 250.46 248.43 253.74 114.01 1,243.19 813.69 519.55 195.64 173.75 190.54
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 534 524 520 904 901 911 860 855 863 850 832
Invested Capital Turnover		 0.88 0.94 0.98 0.75 0.86 0.94 1.08 0.94 1.00 1.05 1.16
Increase / (Decrease) in Invested Capital		 -37 -56 -64 333 367 387 340 -49 -38 -61 -28
Enterprise Value (EV)		 1,229 1,530 1,399 1,753 1,660 1,950 1,837 2,337 2,096 2,012 2,117
Market Capitalization		 1,127 1,457 1,336 1,255 1,162 1,458 1,413 1,988 1,774 1,724 1,883
Book Value per Share		 $21.17 $21.44 $21.73 $19.29 $19.20 $19.23 $20.16 $23.31 $24.07 $25.07 $26.26
Tangible Book Value per Share		 $9.57 $10.80 $11.66 ($10.66) ($9.42) ($8.29) ($6.65) ($2.60) ($0.06) $1.46 $3.73
Total Capital		 756 763 767 1,057 1,053 1,067 1,084 1,126 1,158 1,176 1,208
Total Debt		 298 286 286 627 624 623 622 620 617 614 610
Total Long-Term Debt		 285 285 284 618 615 612 608 605 600 594 589
Net Debt		 77 48 39 473 473 468 398 349 322 288 235
Capital Expenditures (CapEx)		 2.28 -8.93 4.45 4.81 2.39 2.47 4.01 6.10 1.24 6.07 3.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 166 167 170 186 192 191 156 172 198 201 187
Debt-free Net Working Capital (DFNWC)		 387 405 417 340 343 346 379 443 492 527 563
Net Working Capital (NWC)		 374 404 415 331 334 334 366 428 475 508 542
Net Nonoperating Expense (NNE)		 7.05 -3.61 5.91 9.80 7.21 4.87 2.73 1.92 2.87 -0.98 2.24
Net Nonoperating Obligations (NNO)		 77 48 39 473 473 468 398 349 322 288 235
Total Depreciation and Amortization (D&A)		 16 15 15 19 33 23 24 23 23 21 20
Debt-free, Cash-free Net Working Capital to Revenue		 34.17% 32.21% 31.56% 33.57% 31.25% 28.29% 20.86% 20.76% 22.38% 21.74% 19.14%
Debt-free Net Working Capital to Revenue		 79.59% 78.25% 77.40% 61.17% 55.86% 51.31% 50.78% 53.59% 55.75% 57.04% 57.56%
Net Working Capital to Revenue		 76.90% 78.01% 77.09% 59.66% 54.36% 49.62% 48.94% 51.74% 53.77% 54.95% 55.38%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.04 $0.84 ($0.14) ($1.27) ($0.47) $0.70 $0.37 $1.19 $1.24 $1.31 $1.09
Adjusted Weighted Average Basic Shares Outstanding		 18.00M 19.10M 19.32M 19.40M 19.32M 19.61M 19.83M 20.07M 20.05M 20.91M 21.16M
Adjusted Diluted Earnings per Share		 $0.05 $0.82 ($0.14) ($1.27) ($0.45) $0.69 $0.36 $1.13 $1.14 $1.28 $1.05
Adjusted Weighted Average Diluted Shares Outstanding		 18.19M 19.42M 19.32M 19.40M 19.32M 20.05M 20.31M 21.09M 21.23M 21.54M 21.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 21.08M 20.97M 21.04M 21.03M 21.77M 21.66M 21.70M 22.47M 22.42M 22.75M 22.97M
Normalized Net Operating Profit after Tax (NOPAT)		 6.10 11 3.87 -14 -4.39 11 12 18 25 28 27
Normalized NOPAT Margin		 4.63% 7.87% 2.80% -9.29% -2.30% 5.61% 5.83% 7.89% 10.30% 11.95% 9.97%
Pre Tax Income Margin		 0.72% 18.43% -1.66% -21.23% -7.22% 10.14% 4.98% 14.84% 12.74% 16.94% 13.94%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -2.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -1.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -3.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -2.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 8.65% 4.57% 6.02% -22.92% -8.77% -7.72% -15.91% 3.85% 1.48% 0.82% 0.32%
Augmented Payout Ratio		 35.21% 32.98% 46.22% -176.24% -67.94% -66.16% -129.03% 33.22% 17.06% 24.65% 20.84%

Financials Breakdown Chart

Key Financial Trends

ANI Pharmaceuticals (NASDAQ: ANIP) has shown strong recent revenue and profit growth, but the latest balance sheet also reflects a leveraged capital structure and a large acquisition-driven asset base.

Looking across the last four years of quarterly statements, the biggest theme is clear: ANI has moved from a small, sometimes loss-making business in 2022–2023 to a much larger, consistently profitable company in 2025–2026. Revenue has expanded sharply, operating margins have improved, and cash generation has strengthened. At the same time, debt remains meaningful and the company has relied on acquisitions, which adds execution risk.

  • Revenue growth has been impressive. Quarterly revenue rose from about $106.8 million in Q1 2023 to $237.5 million in Q1 2026, showing a much larger operating base.
  • Profitability has improved dramatically. ANI went from losses in some 2022 and 2024 quarters to solid profits in 2025 and Q1 2026, when net income reached $29.5 million.
  • Operating income strengthened meaningfully. Q1 2026 operating income was $38.9 million, up from $34.8 million in Q4 2025 and well above the weaker 2024 periods.
  • Cash flow is healthy. ANI generated $58.4 million in operating cash flow in Q1 2026, after $30.4 million in Q4 2025 and $75.8 million in Q2 2025.
  • Cash and short-term investments are sizable. Q1 2026 cash and equivalents were $311.2 million, with another $14.9 million in short-term investments, giving the company good near-term liquidity.
  • Equity has improved over time. Total common equity reached $562.3 million in Q1 2026, up from $418.6 million in Q1 2025.
  • Gross profit dollars have climbed with sales. Q1 2026 gross profit was $143.9 million, compared with $124.1 million in Q1 2025 and just $69.1 million in Q1 2023.
  • ANI continues to invest in acquisitions. The company spent $5.3 million on acquisitions in Q1 2026, following much larger acquisition spending in some prior quarters. This can support growth, but it also raises integration risk.
  • Intangibles remain a large part of the balance sheet. Intangible assets were $467.2 million in Q1 2026, so future performance will depend partly on how well acquired assets perform.
  • Debt remains elevated. Q1 2026 long-term debt was $594.5 million, with another $19.3 million of short-term debt, so leverage is still a key risk.
  • Interest costs are still meaningful. Q1 2026 cash interest paid was $7.8 million, which can pressure earnings if rates stay high or debt is not reduced.
  • Share repurchases and acquisitions consume cash. In Q1 2026, ANI spent $19.8 million repurchasing common equity and continued to deploy capital into deals, which can limit balance sheet flexibility.
  • Working capital swings can be volatile. Cash from operations has been strong, but it has fluctuated quarter to quarter based on operating assets and liabilities, so earnings quality and cash conversion should be watched closely.

Bottom line: ANI Pharmaceuticals appears to be in a much better operating position than it was two years ago, with strong revenue growth, better margins, and solid cash generation. However, investors should keep an eye on debt levels, acquisition execution, and how much of the earnings growth is supported by ongoing cash flow rather than one-time factors.

08/20/26 04:04 AM ETAI Generated. May Contain Errors.

ANI Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ANI Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

ANI Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $78.34 million in 2025, rising from $15.38 million in 2015. The previous period was -$18.52 million in 2024. View ANI Pharmaceuticals' forecast to see where analysts expect ANI Pharmaceuticals to go next.

ANI Pharmaceuticals' total operating income in 2025 was $111.09 million, based on the following breakdown:
  • Total Gross Profit: $542.06 million
  • Total Operating Expenses: $430.96 million

Over the last 10 years, ANI Pharmaceuticals' total revenue changed from $76.32 million in 2015 to $883.37 million in 2025, a change of 1,057.4%.

ANI Pharmaceuticals' total liabilities were at $899.65 million at the end of 2025, a 5.1% increase from 2024, and a 618.7% increase since 2015.

In the past 10 years, ANI Pharmaceuticals' cash and equivalents has ranged from $7.86 million in 2020 to $285.59 million in 2025, and is currently $285.59 million as of their latest financial filing in 2025.

Over the last 10 years, ANI Pharmaceuticals' book value per share changed from 13.92 in 2015 to 24.07 in 2025, a change of 72.9%.


Related Companies

Financial statements for NASDAQ:ANIP last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
This tiny launch company operates next to SpaceX and Blue Origin
A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...
Freedom Financial | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel